Policy Interventions to Enhance Medical Care for People With Obesity in the United States—Challenges, Opportunities, and Future Directions.
Saved in:
| Title: | Policy Interventions to Enhance Medical Care for People With Obesity in the United States—Challenges, Opportunities, and Future Directions. |
|---|---|
| Authors: | JOLIN, JAMES RENÉ, KWON, MINSOO, BROCK, ELIZABETH, CHEN, JONATHAN, KOKAN, AISHA, MURDOCK, RYAN, STANFORD, FATIMA CODY |
| Source: | Milbank Quarterly. Jun2024, Vol. 102 Issue 2, p336-350. 15p. |
| Subjects: | Policy sciences, Glucagon-like peptide-1 agonists, Health services accessibility, Bariatric surgery, Insurance, Topiramate, Prejudices, Health policy, Medical care, Regulation of body weight, Medicare, Body weight, Nutrition counseling, Patient advocacy, United States. Food & Drug Administration, Orlistat, Drug approval, Conceptual structures, Medication therapy management, Antiobesity agents, Bupropion, Disease relapse, Cognitive therapy, Obesity, Behavior therapy, Medical care costs, Social stigma, Naltrexone, Nutrition |
| Geographic Terms: | United States |
| Abstract: | Policy PointsHealth policymakers have insufficiently addressed care for people with obesity (body mass index ≥ 30 kg/m2) in the United States. Current federal policies targeting obesity medications reflect this unfortunate reality.We argue for a novel policy framework to increase access to effective obesity therapeutics and care, recognizing that, though prevention is critical, the epidemic proportions of obesity in the United States warrant immediate interventions to augment care.Reducing barriers to and improving the quality of existing anti‐obesity medications, intensive behavioral therapy, weight management nutrition and dietary counseling, and bariatric surgery are critical. Moreover, to ensure continuity of care and patient–clinician trust, combating physician and broader weight stigma must represent a central component of any viable obesity care agenda. [ABSTRACT FROM AUTHOR] |
| Copyright of Milbank Quarterly is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | Psychology and Behavioral Sciences Collection |
|
Full text is not displayed to guests.
Login for full access.
|
|
| Abstract: | Policy PointsHealth policymakers have insufficiently addressed care for people with obesity (body mass index ≥ 30 kg/m2) in the United States. Current federal policies targeting obesity medications reflect this unfortunate reality.We argue for a novel policy framework to increase access to effective obesity therapeutics and care, recognizing that, though prevention is critical, the epidemic proportions of obesity in the United States warrant immediate interventions to augment care.Reducing barriers to and improving the quality of existing anti‐obesity medications, intensive behavioral therapy, weight management nutrition and dietary counseling, and bariatric surgery are critical. Moreover, to ensure continuity of care and patient–clinician trust, combating physician and broader weight stigma must represent a central component of any viable obesity care agenda. [ABSTRACT FROM AUTHOR] |
|---|---|
| ISSN: | 0887378X |
| DOI: | 10.1111/1468-0009.12693 |
